Fisher Asset Management
ACAD icon

Fisher Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Fisher Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.7M Sell
699,230
-33,642
-5% -$740K 0.01% 352
2026
Q1 		$16.3M Buy
732,872
+67,785
+10% +$1.62M 0.01% 346
2025
Q4 		$17.8M Buy
665,087
+26,595
+4% +$636K 0.01% 340
2025
Q3 		$13.6M Buy
638,492
+328,181
+106% +$7.76M ﹤0.01% 373
2025
Q2 		$6.69M Sell
310,311
-44,710
-13% -$831K ﹤0.01% 447
2025
Q1 		$5.9M Buy
355,021
+27,516
+8% +$500K ﹤0.01% 471
2024
Q4 		$6.01M Buy
327,505
+132,906
+68% +$2.15M ﹤0.01% 480
2024
Q3 		$2.99M Buy
194,599
+31,980
+20% +$534K ﹤0.01% 536
2024
Q2 		$2.64M Buy
162,619
+9,689
+6% +$156K ﹤0.01% 550
2024
Q1 		$2.83M Buy
152,930
+9,876
+7% +$245K ﹤0.01% 556
2023
Q4 		$4.48M Buy
+143,054
New +$3.42M ﹤0.01% 503

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management's ACAD Position: Q2 2026 in Review

Fisher Asset Management reduced its Acadia Pharmaceuticals (ACAD) stake by 4.6% in Q2 2026, selling an estimated $740K and leaving 699,230 shares worth $17.7M. The position accounts for 0.01% of the portfolio, ranked #352.

Fisher Asset Management first reported a position in ACAD in Q4 2023 and has held it in 11 quarters since. The position peaked at $17.8M in Q4 2025. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Fisher Asset Management held 699,230 shares of Acadia Pharmaceuticals worth $17.7M as of Q2 2026.
  • Fisher Asset Management sold 33,642 Acadia Pharmaceuticals shares in Q2 2026, an estimated $740K.
  • Acadia Pharmaceuticals made up 0.01% of Fisher Asset Management's portfolio in Q2 2026, its #352 holding.
  • Fisher Asset Management first reported a position in Acadia Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Fisher Asset Management's Acadia Pharmaceuticals position peaked at $17.8M in Q4 2025.
  • 352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Fisher Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.